The Conversation (0)
May 28, 2025
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
10 April
Invion Limited
Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases Keep Reading...
22h
Funded Collaboration Agreement with Protect Animal Health
Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
09 October
Repayment of Lind Facility with Successful Capital Raise
Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
07 October
Trading Halt
Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
27 August
Appendix 4E and Annual Report
Invion Limited (IVX:AU) has announced Appendix 4E and Annual ReportDownload the PDF here. Keep Reading...
20 August
Orphan Drug Designation Granted by U.S. FDA for Anal Cancer
Invion Limited (IVX:AU) has announced Orphan Drug Designation Granted by U.S. FDA For Anal CancerDownload the PDF here. Keep Reading...
12h
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...
20 October
Canadian Investment Regulatory Organization Trade Resumption - CRDL
Trading resumes in: Company: Cardiol Therapeutics Inc. TSX Symbol: CRDL All Issues: Yes Resumption (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly... Keep Reading...
17 October
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...
07 October
5 Small-cap Biotech ETFs to Watch in 2025
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
29 August
FY25 Preliminary Results Summary and Company Update
Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
29 August
Appendix 4E
Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
Latest News
Sign up to get your FREE
Invion Limited Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00